Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
2.980
+0.040 (1.36%)
At close: Oct 19, 2026, 4:00 PM EDT
3.040
+0.060 (2.01%)
After-hours: Oct 19, 2026, 4:52 PM EDT
Inventiva Revenue
Inventiva had revenue of 1.31M EUR in the half year ending June 30, 2026, a decrease of -52.23%. This brings the company's total for the last twelve months to 3.62M, down -75.47% year-over-year. In the year 2025, Inventiva had annual revenue of 7.93M, down -46.17%.
Revenue (ttm)
3.62M EUR
Revenue Growth
-75.47%
P/S Ratio
255.54
Revenue / Employee
41,632 EUR
Employees
87
Market Cap
726.76M USD
Revenue by Geography
- China 9.13M 99.2%
- France 69.00K 0.8%
Fiscal year ended Dec 31, 2024 See the full Inventiva breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.93M | -6.80M | -46.17% |
| Dec 31, 2024 | 14.72M | -8.44M | -36.43% |
| Dec 31, 2023 | 23.16M | 4.35M | 23.12% |
| Dec 31, 2022 | 18.81M | 10.31M | 121.32% |
| Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
| Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
| Dec 31, 2019 | 11.29M | 3.91M | 53.02% |
| Dec 31, 2018 | 7.38M | -2.58M | -25.90% |
| Dec 31, 2017 | 9.96M | -4.39M | -30.61% |
| Dec 31, 2016 | 14.35M | 5.69M | 65.66% |
| Dec 31, 2015 | 8.66M | 2.36M | 37.55% |
| Dec 31, 2014 | 6.30M | 1.20M | 23.46% |
| Dec 31, 2013 | 5.10M | 5.06M | 10,977.18% |
| Dec 31, 2012 | 46.06K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 450.89M |
| Geron | 204.56M |
| Ginkgo Bioworks Holdings | 132.42M |
| Apnimed | 115.12M |
| 4D Molecular Therapeutics | 92.01M |
| Lexicon Pharmaceuticals | 41.47M |
| OmniAb | 38.46M |
| Adlai Nortye Group | 18.06M |
IVA News
- 9 days ago - 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead - MarketBeat
- 13 days ago - Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026 - GlobeNewsWire
- 15 days ago - Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test - MarketBeat
- 17 days ago - Inventiva price target raised to $18 from $13 at Truist - TheFly
- 19 days ago - Inventiva Transcript: Stifel 2026 Virtual Cardiometabolic Forum - Transcripts
- 20 days ago - Inventiva (IVA): H1 Results Put Cash Runway and NATiV3 at the Center of the Story - AlphaStreet
- 20 days ago - Inventiva (IVA) Q2 2026 Earnings Call Transcript - The Motley Fool
- 20 days ago - Inventiva price target raised to $21 from $20 at Canaccord - TheFly